KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Receivables (2016 - 2024)

Historic Change in Receivables for Nektar Therapeutics (NKTR) over the last 15 years, with Q4 2024 value amounting to $2.2 million.

  • Nektar Therapeutics' Change in Receivables rose 32062.06% to $2.2 million in Q4 2024 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 149493.67%. This contributed to the annual value of $3.0 million for FY2024, which is 16375.63% up from last year.
  • Nektar Therapeutics' Change in Receivables amounted to $2.2 million in Q4 2024, which was up 32062.06% from $850000.0 recorded in Q3 2024.
  • Over the past 5 years, Nektar Therapeutics' Change in Receivables peaked at $7.7 million during Q1 2022, and registered a low of -$20.2 million during Q2 2022.
  • In the last 5 years, Nektar Therapeutics' Change in Receivables had a median value of -$642000.0 in 2021 and averaged -$1.6 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 173918.5% in 2020, then tumbled by 699263.16% in 2022.
  • Nektar Therapeutics' Change in Receivables (Quarter) stood at -$8.0 million in 2020, then soared by 68.87% to -$2.5 million in 2021, then crashed by 121.86% to -$5.6 million in 2022, then soared by 82.0% to -$999000.0 in 2023, then surged by 320.62% to $2.2 million in 2024.
  • Its Change in Receivables stands at $2.2 million for Q4 2024, versus $850000.0 for Q3 2024 and -$2.4 million for Q2 2024.